C. diff Risk


Oral Bioavailability


Approximate Cost



Usual Dose
1-2 g IV q24h

Bacterial meningitis
2 g IV q12h

Enterococcus faecalis endocarditis (Only as a synergistic agent with ampicillin - NEVER ALONE)
2 g IV q12h

General information

Empiric therapy of:

  • Bacterial meningitis

  •  Nosocomial gram negative infections (except Pseudomonas)

  •  Spontaneous bacterial peritonitis

  •  Pyelonephritis

  •  Hospitalized community or nursing home acquired pneumonia in combination with a macrolide

  • Community-acquired intra-abdominal infections in combination with metronidazole

  •  Diarrhea

  •  Allergy/rash (immediate or delayed)

  •  Cytopenias

  •  Eosinophilia

  •  Hepatic & renal laboratory abnormalities

  •  Pseudocholelithiasis. Unclear clinical significance. Uncommonly symptomatic, but frequently by ultrasound gallbladder sludge

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8.0

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic